RecruitingPhase 3NCT07155525

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

Pancreaticojejunostomy With or Without Modified N-butyl-2-cyanoacrylate Following Pancreaticoduodenectomy in Soft Pancreas: Randomized Controlled Trial


Sponsor

Minia University

Enrollment

194 participants

Start Date

Sep 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria8

  • Patients scheduled for elective pancreaticoduodenectomy for malignant lesions.
  • Intraoperative confirmation of soft pancreatic texture (by surgeon palpation; friable, non-fibrotic pancreas).
  • Age 18-75 years .
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Adequate organ function defined as:
  • Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 3 times upper limit of normal Alanine transaminase (ALT) /Alanine transaminase (ALT)( ≤ 5 times upper limit of normal Serum creatinine ≤ 1.5 times upper limit of normal
  • Informed consent provided.
  • Willingness to comply with study procedures and follow-up requirements.

Exclusion Criteria8

  • Hard pancreatic texture (intraoperative surgeon assessment).
  • Emergency surgery.
  • Previous pancreatic surgery or pancreatic anastomosis.
  • Intraoperative identification of unresectable disease
  • Known allergy to cyanoacrylate or components.
  • Pregnancy or lactation.
  • Active infection or sepsis.
  • Inability to comply with follow-up.

Interventions

DRUGPancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)

* Standard duct-to-mucosa pancreaticojejunostomy performed * Application of 0.5-1.0 mL modified N-butyl-2-cyanoacrylate around the anastomotic site * Adhesive applied circumferentially around the pancreaticojejunal anastomosis * Allow 2-3 minutes for polymerization before proceeding * Standard placement of peritoneal drains

PROCEDUREStandard(duct-to-mucosa) Pancreaticojejunostomy

* Patients undergo duct-to-mucosa pancreaticojejunostomy without additional adhesive following pancreaticoduodenectomy. * Standard placement of peritoneal drains * All other aspects of surgical care identical to experimental arm


Locations(1)

Liver and GIT hospital , Minia University

Minya, Minya Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07155525


Related Trials